|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126683 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-13 17:55:45 |
|
注册时间: Date of Registration: |
2026-06-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
上海地区2型炎症人群过敏性疾病临床特点分析:基于2型炎症标志物筛查的回顾性分析 |
|
Public title: |
Clinical Characteristics of Allergic Diseases Among Individuals with Type 2 Inflammation in Shanghai: A Retrospective Study Based on Biomarker-Based Screening for Type 2 Inflammation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
上海地区2型炎症人群过敏性疾病临床特点分析:基于2型炎症标志物筛查的回顾性分析 |
|
Scientific title: |
Clinical Characteristics of Allergic Diseases Among Individuals with Type 2 Inflammation in Shanghai: A Retrospective Study Based on Biomarker-Based Screening for Type 2 Inflammation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张旻 |
研究负责人: |
张旻 |
|
Applicant: |
Min Zhang |
Study leader: |
Min Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 13482345145 |
研究负责人电话:
Study leader's |
+86 21 63240090 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13482345145@163.com |
研究负责人电子邮件: Study leader's E-mail: |
13482345145@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市虹口区武进路85号上海市第一人民医院北院 |
研究负责人通讯地址: |
上海市虹口区武进路85号 |
|
Applicant address: |
85 Wujin Road, Hongkou District, Shanghai |
Study leader's address: |
85 Wujin Road, Hongkou District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第一人民医院 |
||
|
Applicant's institution: |
Shanghai General Hospital |
||
|
研究负责人所在单位: |
上海市第一人民医院 |
||
|
Affiliation of the Leader: |
Shanghai General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
院伦快【2026】163号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第一人民医院人体试验伦理审查委员会 |
||
|
Name of the ethic committee: |
Shanghai General Hospital Institutional Review Board |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-18 00:00:00 | ||
|
伦理委员会联系人: |
耿雯倩 |
||
|
Contact Name of the ethic committee: |
Geng Wenqian |
||
|
伦理委员会联系地址: |
上海市虹口区武进路85号 |
||
|
Contact Address of the ethic committee: |
85 Wujin Road, Hongkou District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 36126254 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
13262983906@163.com |
|
研究实施负责(组长)单位: |
上海市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市虹口区武进路85号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
85 Wujin Road, Hongkou District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self raised |
||||||||||||||||||||||
|
研究疾病: |
过敏性鼻炎、支气管哮喘、过敏性皮炎 |
||||||||||||||||||||||
|
Target disease: |
allergic rhinitis , asthma, and atopic dermatitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
研究上海地区2型炎症人群过敏性疾病临床特点。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the clinical characteristics of allergic diseases among individuals with type 2 inflammation in Shanghai. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
2021年1月到2025年12月期间就诊于我院门诊或病房,不限制年龄、性别等,满足以下任意一条标准: (1)外周血嗜酸性粒细胞计数高于300/μL; (2)tIgE超过60 KU/L; (3)任意sIgE阳性。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients who visited the outpatient clinics or inpatient wards of our hospital between January 2021 and December 2025 were retrospectively screened, without restrictions on age or sex. Eligible participants were required to meet at least one of the following criteria:; (1) Peripheral blood eosinophil count > 300 cells/μL; (2) Total IgE (tIgE) level > 60 kU/L; (3) Positivity for any specific IgE (sIgE). |
||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||
|
Exclusion criteria: |
None |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-25 00:00:00至 To 2027-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-14 00:00:00 至 To 2027-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过上海市第一人民医院电子采集和管理系统(EDC);网址:192.168.9.140:8802 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC system of Shanghai General Hospital;website:192.168.9.140:8802 |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |